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The association between thyroid cancer and thyroid inflammation has been repeatedly reported and highly debated in the literature.
In fact, both molecular and epidemiological data suggest that these diseases are closely related and this association reinforces that
the immune system is important for thyroid cancer progression. Innate immunity is the first line of defensive response. Unlike
innate immune responses, adaptive responses are highly specific to the particular antigen that induced them. Both branches of
the immune system may interact in antitumor immune response. Major effector cells of the immune system that directly target
thyroid cancer cells include dendritic cells, macrophages, polymorphonuclear leukocytes, mast cells, and lymphocytes. A mixture
of immune cells may infiltrate thyroid cancer microenvironment and the balance of protumor and antitumor activity of these cells
may be associated with prognosis. Herein, we describe some evidences that immune response may be important for thyroid cancer
progression andmay help us identifymore aggressive tumors, sparing the vast majority of patients from costly unnecessary invasive
procedures. The future trend in thyroid cancer is an individualized therapy.
1. Introduction
Immune responses against differentiated thyroid carcinomas
(DTC) and associations between inflammation and DTC
have long been reported [1–4] and evidenced by a mixture
of immune cells frequently found within, inside, or even sur-
rounding primary thyroid tumors [2, 5]. These observations
support the concept that the immune systemmay interfere in
DTC progression [3, 4, 6].
Pathologists have long recognized that some tumors are
marked infiltrated by cells of both innate and adaptive arms
of the immune system, thereby reflecting inflammatory con-
ditions arising in nonneoplastic tissues. In addition, clinicians
have long been realizing that local immune response [1,
6] and concurrent chronic lymphocytic thyroiditis [1, 7]
would be associated with favorable/unfavorable prognostic
profile of patients with DTC. All these bedside observations
stimulated investigations to unveil how the immune response
is established in thyroid cancer andwhat is its influence on the
outcome of patients with DTC.
2. Principles of Thyroid Carcinogenesis
2.1. Epidemiology and Risk Factors. Thyroid cancer accounts
for around 2%of all human cancers [8].Most of these patients
will evolve very well with current therapy; however, 10–30%
of them will present recurrent disease and part of them
will eventually stop responding to radioiodine treatment
and metastasize, contributing to 1,850 deaths due to thyroid
tumors estimated to occur in the USA during 2013 [9].
Ionizing radiation is the most studied and consolidated
risk factor for DTC.The thyroid may be irradiated more than
other tissues because of its position in the body and its ability
to concentrate iodine [10]. Mahoney et al. [11] have reported
that the incidence of thyroid cancer after the Chernobyl
accident has augmented in all areas of the Republic of Belarus
and among all age groups, although children have suffered a
more pronounced increase. Other studies also reported that
there was a peak of PTCs after Chernobyl accident, when
many children were exposed to high radiation doses [10, 12].
In 2011, Schonfeld et al. [13] presented an overview of the
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use of radiation for medical purposes and its significance
for thyroid cancer, especially among children, who seem
to be more susceptible to the effects of ionizing radiation;
however, the authors concluded that X-rays do not seem
to alter DTC risk. Thyroid cancers are one of the most
common second cancers after radiotherapy during childhood
for Hodgkin lymphoma, and significant increased risks of
thyroid cancer have been observed even more than 40 years
after childhood radiotherapy [14]. Several studies have been
associating thyroid cancer with exposure to 131I, which can
cause several atypical molecular alterations in genes such as
RET, NTRK1, RAS, and BRAF [15–17].
Dietary iodine intake is among the possible environmen-
tal influences on the incidence and prevalence of thyroid
disease in general and thyroid cancer in particular [18].
Increasing PTC has also been related to a high iodine intake
[19]. Cardis et al. indicated that iodine deficiency increases
the risk of 131I-related thyroid cancer [20]. These authors
suggested that stable iodine supplementation in iodine-
deficient populations may reduce the subsequent risk of
radiation-related thyroid cancer [20].
Thyroid diseases occur with a marked higher frequency
in women than in men for reasons that are not completely
elucidated. PTC usually manifests during the reproductive
age (30–49 years old), in a ratio of three to five females to one
male and has the highest incidence in premenopausal women
[21, 22]. Although PTC is more frequent in females, male sex
is associated with a higher rate of malignancy among thyroid
nodules [23], and several studies have suggested that male
patients withDTC have worse survival [21, 24, 25]. Studying a
very large cohort (36,725 patients), Oyer et al. [26] concluded
that males with PTC and FTC tend to be older and havemore
advanced-stage disease relative to their female counterparts;
however, there was no difference in disease-specific survival
for men and women when they were compared by disease
stage.
2.2. Molecular Genetic Alterations in Thyroid Cancer. The
MAPK pathway plays an important role in DTC, and three
of its genes (BRAF, RET/PTC, and RAS) can suffer mutually
exclusive genetic alterations which have been implicated in
the pathogenesis of PTC [27]. BRAF mutations are the most
frequent genetic alteration, occurring in approximately 45%
of PTC cases [16]. The most common BRAF mutation causes
a substitution of valine for glutamic acid at position 600
of the protein (V600E), but there are also an A > G
transversion at gene position 1801 (K601E), the fusion with
the A-kinase anchor protein 9 (AKAP9) gene, and small
in-frame insertions or deletions around codon 600 [28–
30]. All of these mutations are able to hyperactivate BRAF
protein causing tumor progression or inducing features of
aggressiveness [31], ultimately leading to the diminished or
nule expression of several thyroid-specific genes, radioio-
dine uptake, and pronounced hypothyroidism [32]. As for
RET/PTC translocations, they are present in sporadic and
radiation-associated PTC, mostly in the last ones [33–35].
RET translocations have not been related to bad prognosis of
PTC but are important as targets for selective inhibition [27].
Several groups studied compounds with inhibitory effects
on RET kinase activity and impairment of cell growth [36–
38]. RAS mutations are not restricted to a specific thyroid
tumor type, being present in follicular adenomas, FTC,
follicular variant of PTC, and at a high frequency in poorly
differentiated cancers and anaplastic thyroid carcinomas [39,
40]. RAS has been shown to activate both the MAPK and
the PI3K/AKT pathways in epithelial cells [27]. Mutations in
PI3KCA gene have been described in 12–23% of ATC cases,
restricted, in general, to undifferentiated thyroid components
[41]. Other groups have reported somatic mutations within
PI3KCA and/or gene amplification in FA, FTC, PTC, and
ATC [41–43]. PI3KCA alterations induce the activation of
PI3K cascade through the enhanced activity of AKT, leading
to thyroid cancer progression and possibly dedifferentiation
[32]. Another gene frequently mutated in aggressive cases
is TP53. Mutations in this gene are commonly observed in
ATCs but are rarely described in DTCs [44–46], making it
possible to hypothesize that this gene plays a role in late steps
of thyroid cancer progression. Amutated p53 gene results in a
marked loss of differentiated phenotype in rat thyroid cell line
(PCCl3), including inhibition of the expression of thyroid-
specific transcription factors [45, 47]. The loss of specific
thyroid features is the main step for dedifferentiation and
formation of very aggressive tumors with bad prognosis.
3. Principles of Tumor Immunology
A close relationship between immune response and cancer
was first proposed by Virchow in 1863. Coley demonstrated
that bacterial products were able to help inoperable can-
cer patients. Indeed, the subsequent application of Bacil-
lus Calmette-Guerin (BCG) and other immunostimulants
showed benefits that led to approval of their use in some solid
tumors such as bladder cancer [48].Thereafter, the capacity of
the immune response to interfere with tumor progression has
been evidenced by clinical and epidemiological reports.Then,
the success of the usage of Herceptin for breast cancer and
Ipilimumab for metastatic melanoma has stimulated many
scientists throughout the world to explore the field of tumor
immunology.
Presence of intratumor or peritumor infiltration of lym-
phocytes is evidence that the immune system may respond
to malignant transformation. Several previous studies have
shown that the high-grade density of CD8+ T cells in cancer
cell nestswas correlatedwith prognosis [49], and the presence
of tumor infiltrating lymphocytes (TILs) was able to predict a
better survival as an independent prognostic factor in various
types of cancers includingmalignantmelanoma [50], ovarian
cancer [51], breast cancer [52], oral squamous cell carcinoma
[53], esophageal cancer [54], and colon cancer [55]. The
understanding of how immune cells and tumor interact came
from different theories, as explained below.
Tumor transplantationmodels provide experimental sup-
port for the finding that tumors could be repressed by
the immune system. These findings strongly suggested the
existence of tumor-associated antigens and formed the basis
of immune surveillance theory, which was postulated by
Burnet and Thomas [56, 57]. Although there is excellent





Figure 1:Three Es theory.This hypothesis suggests that the immune
system and tumors may interact in three different stages. In the first
stage, tumor cells are eliminated by the immune system. Elimination
is followed by the second stage (equilibrium), where a selection
process for less immunogenic tumor variants takes place until
tumors are able to “escape” from immune surveillance (third stage).
mechanisms prevent the outgrowth of tumor cells induced
by horizontally transmitted, ubiquitous, potential oncogenic
viruses, there is much less evidence for immune surveillance
acting against chemically induced tumors in syngeneic mice
[49, 58].
During the malignant transformation, tumor cells may
express tumor-specific and/or tumor-associated antigens.
Tumor-associated antigens are macromolecules more fre-
quently found in tumors, whereas tumor-specific antigens
are macromolecules uniquely expressed in tumors [59]. Even
though this group of antigens may be used as target for
immunotherapy, the most important application of tumor
antigen is for diagnosis or even to monitor therapeutic
efficacy [60].
In 2002, Dunn et al. proposed the cancer immunoediting
hypothesis. According to this hypothesis, cancer immu-
noediting is responsible for both eliminating tumors and
sculpting the immunogenic phenotypes of tumors that even-
tually form in immunocompetent hosts [61].This hypothesis,
called as “three Es theory,” suggests that the immune system
and tumors may interact in three different stages (Figure 1).
Tumor cells are initially eliminated by the immune system
before becoming clinically detectable. This is equivalent
to immunosurveillance. Elimination is then followed by
an equilibrium phase, where a selection process for less
immunogenic tumor variants takes place until tumors finally
“escape” from immune surveillance [61]. Generally, by the
time a tumor is clinically evident, it has escaped the host
immune response and may even manipulate the immune
system to promote tumor progression [62].
Clinical and experimental research has shown that tumor
escape from immune recognition and tumor-mediated sup-
pression of antitumor immunity can pose a significant obsta-
cle to successful cancer therapy. Poschke et al. classified tumor
escape from the immune system in two distinct mechanisms:
camouflage and sabotage. Camouflage is active at the level of
the tumor and can be ascribed to abnormalities in the expres-
sion of major histocompatibility complex (MHC) class I-
restricted antigens, enabling tumors to take on a “stealth” phe-
notype, hiding from immune cell detection [63]. The other
mechanism results from the tumor ability of progressing the
host immune system to “sabotage.” Some tumors have the
ability to manipulate parts of the body’s own immune system
to protect themselves against the host immune response. By
doing that, tumors recruit or even induce immune cells like
myeloid-derived suppressor cells (MDSCs) or regulatory T
cells (Tregs). Under normal conditions, MDSCs and Treg
serve as safeguards against overwhelming inflammation and
lead to immune resolution [63].The installation of these cells
contributes to turning the permissive microenvironment for
tumor progression.
One important mechanism of immune escape is T-
lymphocyte dysfunction. T-lymphocytes are a common find-
ing among TILs. The majority of T-cells are naive cells
ignorant to the tumor, while a portion of T-cells show
signs of activation but are functionally anergic or tolerant
to the tumor [64]. Tumor-induced T-cell tolerance may
be directed to self- and nonself-antigens [65–67]. Lee et
al. studied anergic CD8+ T-lymphocytes. They identified
circulating CD8+ T-cell populations specific for tumor-
associated antigens in six of eleven patients with metastatic
melanoma. These CD8+ T-lymphocytes presented two phe-
notypes: one, typical for memory/effector T-cells; the other,
a previously undescribed phenotype expressing both naive
and effector cell markers. Although these cells with latter
phenotype have many of the hallmarks of effector T-cells,
they were functionally unresponsive, unable to directly lyse
melanoma target cells or produce cytokines in response to
mitogens, suggesting that this population has been selectively
rendered anergic in vivo. It should be highlighted that
peptide stimulation of TAA-specific T-cell populations in
other patients failed to induce substantial upregulation of
CD69 expression, indicating that these cells may also have
functional defects, leading to blunted activation responses
[68].
Interestingly, Mortarini et al. observed that tumor-invad-
ed lymph nodes of patients with melanoma were enriched
with TILs. However, in tumor-invaded lymph nodes of
most patients, CD8(+) T-cells directed to melanocyte dif-
ferentiation antigens or to tumor-restricted antigens showed
a precursor phenotype. Only in 7 of 23 cases antigen-
specific CD8(+) T-cells in invaded lymph nodes showed
a predominant preterminally differentiated phenotype. In
the latter subset of patients, they detected staining for
perforin and granzyme B in the cytoplasm of only a frac-
tion of CD8+ cells present in neoplastic tissue. In these
patients, they found perforin and granzyme B expressed
on a higher fraction of CD8+ lymphocytes located in the
residual lymph node tissue surrounding the invading tumor,
with remarkably fewer positive lymphocytes among those
intermingling with neoplastic tissue. In addition, analysis of
invaded lymph node sections for morphological evidence
of tumor necrosis and/or regression or apoptosis failed to
show evidence for tumor destruction in all of the lesions,
suggesting that incomplete CD8+ T-cell maturation and
reduced expression of cytotoxic factors in CD8+ T-cells
may impair tumor cell destruction in invaded lymph nodes
[69].
4 Scientifica
4. Relationship between Chronic Lymphocytic
Inflammation and DTC
Hashimoto’s disease and Graves’ disease are the two most
common forms of autoimmune thyroiditis. Both are char-
acterized by lymphocytic infiltrate and autoreactivity against
thyroid autoantigens.
Chronic lymphocytic thyroiditis (CLT) is an autoimmune
disease characterized by fibrosis, lymphocytic infiltration,
and parenchymal atrophy of thyroid tissue. Hashimoto’s
thyroiditis (HT) is characterized by infiltration of the thyroid
gland by immune cells, often followed by hypothyroidism
due to destruction and eventual fibrous replacement of the
parenchymal tissue. In HT, the immune system produces
autoantibodies to thyroid-specific antigens, considering that
thyroglobulin (Tg) and thyroperoxidase (TPO) are the two
primary antigens in thyroid autoimmunity [70, 71]. Its
unclear etiopathogenesis strongly indicates an autoimmune
background, associated with T-helper lymphocyte (CD4+)
activation by class II human leukocyte antigen system cells
(MHC class II: HLA-DR3, HLA-DR4, and HLA-DR5). Con-
versely, cells recruit cytotoxic lymphocytes (CD8+), thus
facilitating a release of cytokines that damage thyroid follicu-
lar cells and activating B lymphocytes [72].
HT is characterized by a gradual loss of thyroid function,
goiter, and T-cell infiltration in histology, affecting women
more often than men, with a sex ratio of 7 : 1, and occurring
in genetically susceptible populations, but lacking a strong
association with HLA. The overridden feature of HT is
the progressive depletion of thyroid epithelial cells, which
are gradually replaced by mononuclear cell infiltration and
fibrosis [73, 74]. In thyroiditis, especially HT, parenchyma
of thyroid gland is progressively lost and replaced by cells
of the inflammatory infiltrate that produce chemokines,
cytokines, and growth factors, most of which are under NF-𝛽
transcriptional control.The persistent stimulation of residual
thyrocytes with suchmolecules could induce the activation of
NF-𝛽 in follicular cells, thereby creating a functional network
between thyroid epithelial cells and inflammatory cells [74].
A functional relationship between chronic inflammation
and cancer was first proposed by Virchow, 1863, and has been
sustained by clinical and epidemiological evidence [4, 75–79].
The relationship between CLT and PTC was first proposed
by Dailey et al., 1955 [80]. Since this initial description,
the association between the diseases has been repeatedly
reported and highly debated in the literature, remaining
controversial. However, it is important to distinguish two
arising questions: (A) is chronic lymphocytic thyroiditis a
risk for thyroid cancer development? (B) Would concurrent
chronic lymphocytic thyroiditis be associated with favor-
able/unfavorable prognosis or patients with thyroid cancer?
4.1. Is Chronic LymphocyticThyroiditis a Risk forThyroid Can-
cer Development? The follicular epithelium in CLT is not
homogenous throughout the entire organ and incidental
multifocal papillary microcarcinomas are often identified. In
addition, some reports from clinical observations suggest
that atypical lesions that are not microcarcinomas should be
classified as either reactive or premalignant “dysplastic” foci
[81]. According to Chui et al., it is not unusual to observe
distinct microscopic foci of follicular epithelial proliferations
in areas of severe inflammation, which lack invasive growth,
papillary architecture, or intranuclear pseudoinclusions, and
thus do not qualify as papillary microcarcinoma. Chui et
al. proposed designating these small atypical lesions as “fol-
licular epithelial dysplasia.” Follicular epithelial dysplasia is
morphologically distinct from the surrounding parenchyma
and is often found in patients with severe CLT andmultifocal
papillary microcarcinoma [81]. They found that follicular
epithelial dysplasia lesions were positive for TTF-1 and
thyroglobulin, though some also expressed p63. Similar to
PTC, strong diffuse staining was observed for HBME-1,
cytokeratin 19, galectin-3, and cyclin-D1. In contrast, normal
thyroid, reactive atypia, and follicular nodular disease were
negative or, at most, exhibited focal weak staining for HBME-
1, cytokeratin 19, and galectin-3. The results of this study
showed the presence of atypical microscopic lesions in
CLT with an immunohistochemical profile similar to PTC,
suggesting the idea of a premalignant lesion preceding PTC,
arising in the context of severe chronic inflammation [81].
What do epidemiological studies tell us?
It is not a novelty that CLT is a risk for several types of
cancer. A number of studies have examined the possible asso-
ciation of CLT with subsequent types of cancer. In fact, CLT
is associated with an increased risk formyeloproliferative and
lymphoproliferative neoplasms [82], malignant lymphoma of
the thyroid [82–84], and breast cancer [85].
In retrospective studies, the rates of malignancy in thy-
roid nodules in patients having HT ranged from 0.5% to
53%; in many [5, 86–90], but not all [56, 91], the rate of
malignancy in thyroid nodules was considered to be higher if
there was concomitant HT than if there was noHT. Anil et al.
[92] performed a single-center prospective study. Prospective
data were gathered on all patients newly diagnosed with
thyroid nodules who were sent for fine-needle aspiration
cytology (FNAC). If a patient had at least one positive thyroid
autoantibody, then the patient was defined as havingHTwith
thyroid nodules.Therewere 164 patientswith thyroid nodules
associated with HT (HT group).There were 551 patients with
thyroid nodules withoutHT (control group).Themalignancy
rate of the nodules in HT group was 1.0% and that of the
nonautoimmune control group was 2.7%, which was not
significant. A possible limitation of this study was that only
4.9% of our HT group and 10% of our control group had
thyroidectomy for their thyroid nodule(s) [92].
Boi et al. [90] assessed the association between thyroid
autoimmunity and thyroid cancer in a retrospective series
of unselected thyroid nodules submitted to FNAC to avoid
the selection bias of surgical series. Ultrasound- (US-) guided
FNACs were obtained from 590 patients with single thyroid
nodules and positive (ATA+, 𝑛 = 197) or negative (ATA−,
𝑛 = 393) serum anti-thyroid antibody (ATA). A higher
prevalence of indeterminate risk ofmalignancy (28.9% versus
21.4%, 𝑃 < 0.05) and suspected malignancy (18.8% versus
9.2%, 𝑃 < 0.001) and lower prevalence of low risk or
benign cytology (52.3% versus 69.5%, 𝑃 < 0.001) were found
in ATA+ versus ATA− nodules, respectively. Multivariate
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logistic regression analysis evidenced that ATA+ conferred
a significant risk of malignant cytology or suspicion of
that, independently of age and sex. In 106 patients where
thyroidectomy was carried out, thyroid cancer was found in
54/61 (88.5%) patients with malignant cytology nodules or
suspicion of them, with similar positive predictive value for
cancer in ATA+ (96.4%) and ATA− (81.8%) nodules [72].
Recently, Chen et al. [93] performed a nationwide cohort
study. The Taiwanese national health insurance research
database was used to identify 1521 newly diagnosed HT
patients from 1998 to 2010 and 6084 frequency-matched
non-HT patients. Hashimoto’s thyroiditis patients were more
likely to be diagnosed with thyroid and colorectal cancer,
with an adjusted hazard-ratio of 11.8 and 4.76, respectively.
Specifically, the HT cohort had a 49.4-fold risk of developing
thyroid cancer during the first 3 years when compared with
the non-HT cohort. According to the authors, the increased
thyroid cancer risk appears in early years, since HT has been
diagnosed due to the coincident findings of thyroid cancer.
This may reflect the result of early thyroid cancer diagnosis
from hard investigation by diagnosis and treatment of HT
[93].
4.2. Would Concurrent Chronic Lymphocytic Thyroiditis Be
Associated with Favorable/Unfavorable Prognosis or Patients
withThyroid Cancer? It remains unclear whether the associa-
tion with a CLT or even an autoimmune disorder could affect
the prognosis of DTC. In fact, a worse prognosis was reported
in some series [94, 95], whereas most studies showed either a
protective effect of thyroid autoimmunity [6, 58, 96, 97] or a
similar behavior between cancer with and without thyroiditis
[3, 4].
At the end of a mean follow-up of 8.9 ± 2.2 years, in
a retrospective study comparing 85 Chinese patients with
both PTC and HT and 1,708 PTC patients without HT
and 8 patients with follicular thyroid carcinoma (FTC) and
HT and 201 FTC without HT, Kim et al. evidenced that
patients presenting concurrentHThad less aggressive tumors
and a better outcome [49]. In addition, in a retrospective
analysis comparing 195 patients with PTC, Yoon et al. showed
that patients presenting concurrent CLT had less aggressive
tumors [98].
In our cohort, the presence of concurrent CLT was also
significantly correlated with favorable prognostic features
including female gender, no extrathyroidal tumor inva-
sion, absence of metastasis at diagnosis, and small tumors,
thus confirming the tight relationship between concurrent
autoimmunity and histopathological features of low aggres-
siveness [99]. Using the same criteria introduced by Huang et
al. to define recurrence, metastasis, and disease-free survival,
a log-rank test also confirmed that the absence of CLT
was more frequent in our patients who had recurrences,
suggesting that autoimmune activity against the gland may
exert a protective effect on the outcomeofDTCpatients [100].
Recently, Dvorkin et al. [101] underwent a retrospective
study investigating 753 patients with DTC divided into two
groups of patients with and without HT at diagnosis. HT
was associated with smaller primary tumor and less lymph
node involvement at presentation. When matched groups
were compared, patients with HT received less additional
radioactive iodine treatments and showed lower rates of
persistence at 1 year and higher rates of disease remission
at the end of follow-up. Regarding multivariate analysis, HT
was predictive of a lower rate of lymph node involvement
and persistent disease at the end of follow-up, suggesting that
HT is associated with a less aggressive form of differentiated
thyroid cancer and a better long-termoutcome. Likewise, Lun
et al. [102] performed a case-control study of 2478 patients
who underwent thyroidectomy. Comparedwith patients with
benign thyroid nodular disease, patients with PTC showed
a significantly higher prevalence of HT. Patients with PTC
and HT were younger, with female predominance, and
had smaller sized tumors with less advanced TNM stage
when compared with those without HT, indicating a better
prognosis.
5. Molecular Link between
Inflammation and DTC
Both a causal association and a noncausal association
between thyroid cancer and CLT have been proposed. The
molecular mechanism that links inflammation and cancer is
not completely clear so far. A link between thyroid cancer,
in particular the PTC histotype, and thyroid autoimmunity
has long been recognized, although the precise relationship
between the two diseases remains subject of debate. Herein,
we list some evidences of molecular mechanisms that may be
involved in both thyroid cancer and thyroid autoimmunity.
Pathways of immune activation could exert a role in thy-
roid cancer and CLT link. Toll-like receptor (TLR) comprises
a family of cell surface receptors involved in the recognition
of pathogen-associated signature molecules that signal the
activation of innate and adaptive immunity [103–107]. TLR
family consists of more than ten members, and TLR3 had
been reported to be restricted primarily to dendritic cells
of the immune system [107, 108]. Harii et al. showed that
TLR3 can be functionally overexpressed in cultured human
thyrocytes by stimuli. Immunohistochemistry showed that
TLR3 protein is overexpressed in human thyrocytes sur-
rounded by immune cells in all patients diagnosed with
Hashimoto’s thyroiditis, suggesting that TLR3 overexpression
can induce an innate immune response in thyrocytes, which
may be important in the pathogenesis of HT and in immune
cell infiltrates [103]. McCall et al. showed that PTC cells
basally express TLR3 RNA and that TLR3 signal systems are
functional in these cells. High basal TLR3 levels and TLR3
signals capable of increasing cytokines and chemokines in
PTC cells in vitro are consistent with the existence of immune
cell infiltrates in vivo, based on related studies suggesting
that elevated TLR3/TLR3 signals in HT are associated with
immune cell infiltrates [109].
Several authors have found RET/PTC rearrangements in
nonneoplastic thyroid lesions, such as CLT [110–112]. Muzza
et al. investigated clinical and molecular features of 128
patients with PTC and concurrent CLT and 215 patients
with PTC alone. The two groups did not show significant
differences in clinical and prognostic features, whereas they
harboured a significantly different genetic background, with
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RET/PTC1 being more represented in PTCs associated with
autoimmunity andBRAF(V600E) in patients with PTC alone.
A RET/PTC rearrangement was also found in 41% of non-
neoplastic thyroid tissues, contralateral to tumors harbouring
either RET/PTC or BRAF mutations. The strong association
between RET/PTC1 and thyroiditis points to a critical role
of this oncoprotein in the modulation of the autoimmune
response [113]. Rhoden et al. investigated samples of both
CLT and PTC. They found that low-level RET/PTC recom-
bination occurs in nonneoplastic follicular cells in CLT and
in a subset of PTC, suggesting that overlapping molecular
mechanisms may govern early stages of tumor development
and inflammation in the thyroid [114]. Kang et al. investigated
the RET/PTC-RAS-BRAF in oxyphil cells in the vicinity of
large lymphoid HT infiltrates and in malignant PTC cells.
The expression of RET, nuclear RAS, and ERK proteins is
greatly enhanced in both PTC and HT oxyphil cells. Then,
the RET/PTC-RAS-BRAF cascade may be associated with
the development of PTC and oxyphil cell metaplasia in HT.
These results show the possibility of amolecular link between
oxyphil cell metaplasia in HT and the progression of PTC
[115].
Different mechanisms could also explain the association
betweenCLT and RET/PTC rearrangement.The first hypoth-
esis is that inflammationmight facilitate the rearrangement. It
is worth noting that the production of free radicals, cytokine
secretion, cell proliferation, and other phenomena correlated
with inflammationmight predispose to the rearrangement in
follicular cells [116]. It is well known that leukocytes recruited
under an inflammatory scenario physiologically secrete reac-
tive oxygen species and reactive nitrogen species. However,
these highly reactive molecules induce the production of
peroxynitrite and other mutagenic agents, leading to DNA
damage [117]. If tissue damage persists, these free-radicals
secreted by immune cells may induce point-mutations, DNA
rearrangements, and double-strand breaks [116, 118].
Guarino et al. proposed that cytokines and chemokines
released by inflammatory tumor stroma could sustain the
survival of thyroid cells in which RET/PTC rearrangements
randomly occur, thereby allowing the selection of clones
that acquire additional genetic lesions and become resistant
to oncogene-induced apoptosis [116], which is the second
hypothesis. In fact, some studies suggest thatRET/PTCmight
induce apoptosis [119, 120]. Some studies suggest that thyroid
cancer cells, like other epithelial cancer cells, may produce
inflammatory factors thatmay facilitate cell survival, prevent-
ing apoptosis. These data reinforce this second hypothesis
of interaction between RET/PTC rearrangement and thyroid
inflammation. Stassi et al. demonstrated that thyroid cancer
variants produced interleukin-4 and interleukin-10, which
increased antiapoptotic molecule (Bcl-2 and Bcl-xL) levels
and protected thyroid cells from chemotherapeutic agents
[121]. Conticello et al. found that IL-4 protects tumor cells
(primary prostate, breast, and bladder cancer) from CD95-
and chemotherapy-induced apoptosis by the upregulation of
antiapoptotic proteins, such as cFLIP/FLAME-1 and Bcl-x(L)
[122]. Todaro et al. identified the fact that primary epithelial
cancer cells from colon, breast, and lung carcinomas express
high levels of the antiapoptotic proteins PED, cFLIP, Bcl-xL,
and Bcl-2. These cancer cells produced interleukin-4 (IL-4),
which amplified the expression levels of these antiapoptotic
proteins and prevented cell death induced upon exposure to
drug agents. Furthermore, exogenous IL-4 was able to upreg-
ulate the expression levels of these antiapoptotic proteins
and potently stabilized the growth of normal epithelial cells,
making them apoptosis-resistant, suggesting that IL-4 acts as
an autocrine survival factor in epithelial cells [123].
The third hypothesis is that RET/PTC rearrangement
might induce chronic inflammation. This hypothesis is fairly
supported by literature, since many investigations suggested
that RET/PTC would favor the proinflammatory microenvi-
ronment through production of different molecules by thy-
rocytes [124–127]. In fact, Russell et al. found that RET/PTC3
alone increases nuclear NF-kappaB activity and secretion of
MCP-1 and GM-CSF. In addition, transfer of RP3-expressing
thyrocytes into mice in vivo attracted dense macrophage
infiltrates, leading to rapid thyroid cell death [128]. The same
group of authors found that IL1-alpha, IL1-beta, IL6, TNF-
alpha, and the Cox2 enzyme are produced by RET/PTC3-
transgenic thyroid tissue, but absent from nontransgenic thy-
roids, supporting the notion that oncogene-induced cytokine
secretion is important for the development and progression
of thyroid carcinomas in genetically permissive hosts [129].
Genes coding for proteins involved in the immune response
(prostaglandin E2, microsomal prostaglandin E2, cyclooxy-
genase 2, and IL24) have been suggested to be induced by
RET/PTC, indicating that the expression of the oncogenic
fusion protein RET/PTC is critical not only in thyroid cancer
pathogenesis but also in the elicitation of inflammatory
response [130–132].
𝐵𝑅𝐴𝐹
𝑉600𝐸 mutation is a common genetic alteration in
PTC. Kim et al. found that, in Korean patients with PTC,
𝐵𝑅𝐴𝐹
𝑉600𝐸 mutation is associated with a lower frequency
of background HT [133]. Likewise, Muzza et al. found that
𝐵𝑅𝐴𝐹
𝑉600𝐸 is more represented in PTC without concurrent
autoimmunity [113]. In fact, studies on melanoma cells have
given clues about mechanisms linking BRAF mutation and
immune response; and IL-10, VEGF, IL-6, and IL-8 are
thought to be induced by 𝐵𝑅𝐴𝐹𝑉600𝐸 mutation [134, 135].
The genomic alterations in BRAF-MAPK signaling path-
way have been recently demonstrated to be associated with
immune escape mechanisms. Smallridge et al. performed
a RNA sequencing in order to identify genes differen-
tially expressed between BRAF-mutant and BRAF wild-type
tumors and to correlate changes to patient clinical status.
Immune/inflammatory pathways were expressed at a lower
level in BRAF-mutant tumors due to either suppression
of immune/inflammation genes in BRAF-mutant tumors
or increased expression by the tumor or by infiltrating
lymphocytes in BRAF wild-type tumors [136]. Interestingly,
the authors observed that major histocompatibility complex,
class I, G (HLA-G) gene, a nonclassical HLA class 1 molecule,
was overexpressed in the BRAF-mutant tumors [136]. HLA-
G evokes several immunosuppressive functions, including
inhibition of cytotoxic CD8+ T cells and natural killer cells,
altering dendritic cell function, shifting from Th1 to Th2 T
cells, and favoring the promotion of immune escape. They
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Figure 2: COX-2 is a catalyzing enzyme that converts cellular
arachidonic acid to prostaglandin, contributing to trigger inflam-
mation. Many reports have demonstrated that COX-2 is not
only responsible for cell proliferation and transformation but also
responsible for inducing angiogenesis. In addition, migration and
invasiveness have been associated to overexpression of COX-2.
would be directly responsible for impaired immune sur-
veillance in BRAF-mutant compared with BRAF wild-type
tumors [136].
Special attention should be given to cyclooxygenase-
2. Cyclooxygenases (COX) components of the arachidonic
acid cascade are a family of catalyzing enzymes that convert
cellular arachidonic acid to prostaglandin. There are two
major cyclooxygenases, COX-1 and COX-2 [137]; COX-2
is an inducible gene [138]. Recently, it has been reported
that COX-2 is overexpressed in many human tumors [139–
142]. This result has suggested that COX-2 may play an
important role in the carcinogenesis and progression of
tumors (Figure 2). Some reports have observed that COX-2 is
not only responsible for cell proliferation and transformation
but also for inducing angiogenesis [143, 144]. In a chemical-
induced thyroid carcinogenesis model, Ota et al. observed
that COX-2 might play important roles in follicular cell
proliferation but do not affect tumor induction [145].
Although some reports have suggested that COX-2
expression is not different among thyroid lesions [146], Ji
et al. observed that COX-2 expressions in undifferentiated
carcinomas and medullary carcinomas were higher than in
PTC and FTC. In addition, the expression of COX-2 in
thyroid adenomas was higher than that in normal tissues.
These findings suggest that overexpression of COX-2 may be
an early event in the progression of thyroid neoplasms [147].
A close relationship between COX-2 and VEGF expression
was also noted [147]. Likewise, Siironen et al. observed that
VEGF-C expression correlated strongly with COX-2 expres-
sion [148]. Cornetta et al. analyzed COX-2 expression in
twenty paraffin-embedded human tissue specimens, includ-
ing normal, inflammatory, and neoplastic thyroid sections.
Immunohistochemical staining confirmed the presence of
COX-2 in thyroid epithelial neoplasms, including PTC and
FTC. Moreover, COX-2 expression was observed in patients
with Hashimoto’s thyroiditis but not observed in normal
thyroid tissue, multinodular goiter, or anaplastic carcinoma,
suggesting that COX-2 expression in both of these thyroid
pathologies may provide a basis for the relationship between
carcinogenesis and autoimmunity [149].
Ito et al. studied COX-2 expression in both differentiated
and undifferentiated thyroid cancers. They observed that
COX-2 expression was reduced in cases with old age, large
size, advanced stage, satellite tumors, and the presence of
solid, scirrhous, or trabecular growth patterns. Undifferenti-
ated carcinomas less frequently overexpressed COX-2 [150].
Lim et al. observed an association between the absence
of COX-2 expression and multiplicity and bilaterality in
papillary thyroid microcarcinomas [151].
Kajita et al. investigated COX-2 expression in PTCs and
matching normal tissues. COX-2 protein, but not mRNA
expression, was greater in PTC when compared with normal
thyroid tissues. From in vitro study, they concluded that
COX-2 also has a role in PTC growth, since a specific
inhibitor of COX-2 regulates PTC cell proliferation [152].
Conversely, Scarpino et al. investigated the biological role
of COX-2 in PTC cells by treating PTC cell lines with the
specific COX-2 inhibitor NS-398. It was found that COX-2
inhibitor treatment significantly reduced the migration and
invasiveness of tumor cells but did not alter cell proliferation
[153].
In contrast to DTC, anaplastic thyroid carcinoma is one
of the most aggressive neoplasms in humans and it accounts
for 5–15% of primary malignant thyroid tumors [154]. Since
anaplastic thyroid carcinoma is a rare cancer, the small
number of available cases has impaired the opportunity to
better understand tumor biology and the natural history
of this disease. In addition, the factors that may affect the
response to treatment and survival are not well known.
There are tiny evidences that immune system may be evoked
in ATC. Significant amounts of colony-stimulating factor
and IL-1 alpha were detected in the conditioned media of
undifferentiated giant cell carcinoma of the thyroid [155], as
suggested by case report [156]. Sato et al. reported two cases
of anaplastic thyroid carcinoma associated with neutrophilia
and elevated IL-6 and macrophage colony-stimulating factor
[157]. Immunohistochemical staining revealed that carci-
noma cells themselves produce IL-6 regardless of the types of
carcinoma cells [157]. Suzuki et al. obtained peripheral blood
mononuclear cells from 49 patients with thyroid cancer, 18
patients with noncancerous thyroid diseases, and 22 healthy
volunteers. The MDSC levels were found to be higher in
patients with any type of thyroid cancer, patients with
anaplastic thyroid carcinoma, and patients with medullary
thyroid carcinoma when compared to patients with non-
cancerous thyroid diseases, suggesting that MDSCs could be
new targets for immunotherapy against anaplastic thyroid
carcinoma [158]. However, further studies are required to
verify this hypothesis.
6. Immune Cell Infiltration and DTC
Innate immune response is a branch of the immune sys-
tem that protects the host in a nonspecific manner. Innate
immunity is the first line of defensive response, and effective
mechanisms engaged in innate immune response are natural
barriers (e.g., skin, gastric mucosa, and respiratory mucosa)
and some immune cells (e.g., neutrophils, eosinophils, and
















Figure 3: Mixture of immune cells may infiltrate thyroid cancer
microenvironment. Some cells (red arrow) may activate different
protumor mechanisms that enhance tumor progression. On the
other hand (blue arrow), some cells may lead to antitumor immune
response that is associated with favorable prognosis.
that directly target cancer cells include natural killer cells
(NK), dendritic cells (DC), macrophages, polymorphonu-
clear leukocytes (including neutrophils, eosinophils, and
basophils), mast cells, and cytotoxic T lymphocytes. NK cells,
DC, polymorphonuclear cells, mast cells, and macrophages
are first-line effectors to damaged cells and cancer cells
(Figure 3) [159].
The importance of the innate immune system in limiting
cancer progression has been highlighted recently with the
following direct molecular interactions between cancers and
innate immune effector cells [159]. Probably tumors are able
to sense the innate immune system. Innate immunity is
thought to produce signals that drive antigen presentation
toward induction of adaptive immune response. The field
of innate immune sensing is growing rapidly, with several
distinct families of proteins having been identified and
additional family members still uncharacterized [160].
Apetoh et al. described, in bothmice andhumans, that the
activation of tumor antigen-specific T-cell immunity involves
secretion of the high-mobility-group box 1 alarmin protein
by dying tumor cells and the action of high-mobility-group
box 1 on toll-like receptor 4 (TLR4) expressed by DCs.
During chemotherapy or radiotherapy, DCs require signaling
through TLR4 and its adaptorMyD88 for efficient processing
and cross-presentation of antigen from dying tumor cells
[161]. Then, TLR4 would be an important key for antitumor
effective immune response.
Toll-like receptors belong to a family of receptors that
take part in innate and adaptive immunity by activating both
T- and B-cell-mediated immune responses [4]. A minimum
of 11 human TLRs are activated by various bacterial and
viral components and also by endogenous factors [162–
164]. The activation of TLR-2 and TLR-4, the principal
receptors for bacterial antigens (bacterial lipopolysaccha-
rides), leads to secretion of cytokines, chemokines, and other
proinflammatory mediators [4]. Hagstro¨m et al. studied the
immunohistochemical expression of TLR-2 and TLR-4 in
127 follicular thyroid neoplasms, both in adenomas and in
carcinomas including oxyphilic tumors. In follicular thyroid
neoplasias, TLR-2 and TLR-4 expression was predominantly
cytoplasmic. Patients for which tumors were negative for
TLR-4 presented with 5-year survival of 67%, whereas
patients for which tumors were positive for TLR-4 presented
with 5-year survival of 92%. TLR-2 expression showed no
correlation with any clinical or histological parameters in
follicular thyroid carcinoma and follicular thyroid adenoma
[4]. TLR-2 and TLR-4 mRNA and protein expression have
been reported in thyroid cells in vitro [165, 166], and these
TLRs promote tumor progression in cancer by activating
cell proliferation and taking part in tumor invasion [162,
167]. Lack of expression, however, may imply immune cell
recruitment failure and may lead to invasion of unattended
tumor cells [4].
Human leukocyte antigen (HLA, also known as major
histocompatibility complex class I) plays a pivotal role in
immune tolerance and a paradoxical part in cancer. Avoiding
HLAexpression could prevent tumor cells destruction, acting
in favor of immune evasion. Dardano et al., studying 183
PTC patients, observed that those with detectable plasma
soluble HLA-G levels showed a higher aggressive behavior
than those without [168]. HLA expressed by tumor cells was,
according to Nunes et al., significantly associated with an
increased occurrence of lymph node metastasis and capsular
invasion [169]. These results suggest that abnormal HLA
expression may be a tumor mechanism used to impair
antitumor immune response and HLAmay be highlighted as
a potential marker of aggressiveness and poor prognosis.
6.1. Natural Killer Cells. Natural killer cells are important
effector cells of innate immunity. They are able to recognize
and destroy pathogens [170]. Phenotypically, NK cells are
defined by the expression of CD16 andCD56 surfacemarkers,
which form a lymphocyte subpopulation without specific
markers for B- or T-cells, and NK cells lack the TCR/CD3
complex [171]. Functionally, NK cells are able to produce
several cytokines, such as tumornecrosis factor-𝛼, interferon-
𝛾, and granulocyte-macrophage colony-stimulating factor
(GM-CSF) [172]. The emerging notion is that NK cells are
not only cytolytic effector cells against microbe-infected
cells or tumor cells. Rather, NK cell-mediated cytotoxicity
and cytokine production impact DC, macrophages, and
neutrophils and endow NK cells with regulatory function,
affecting subsequent antigen-specific T- and B-cell responses
[172]. Gogali et al. investigated infiltration of NK cells in
thyroid glands of 65 patients with PTC and 25 with thyroid
nodular goiter. PTCswere enrichedwithNKcells and authors
found an increased number of NK cells in PTC tissue when
comparedwith thyroid nodular goiter tissue. In addition, they
observed an inverse correlation between NK cell infiltration
and tumor stage, with decreased NK cell infiltration in
advanced stages [173].This result suggests the weakness of the
innate immune response towards cancer spread in advanced
stages.
NK cells can be divided into two functional subsets based
on their surface expression of CD56. CD56dim are cytotoxic
cells, whereas CD56bright play an immunoregulatory role
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[174]. These NK cell subsets present differences in their
cytotoxic potential, cytokine production, and response to
cytokine activation [175, 176]. Liapi studied the distribution
of cytotoxic and immunoregulatory NK subpopulations in
tissue and blood samples frompatientswith PTC andnodular
goiter. The distribution of immunoregulatory and cytotoxic
NK cell subpopulations in the peripheral blood was similar
in patients with PTC, nodular goiter, or healthy donors.
PTC microenvironment presented increased immunoreg-
ulatory NK cells. Comparison of NK cell subpopulations
between PTC and goiter revealed that cytotoxic cell numbers
were significantly higher in goiter than in PTC. In con-
trast, immunoregulatory cells showed a higher infiltration
in PTC than goiter tissues, pointing to the fact that an
immunoregulatory pattern of NK cells is required for thyroid
carcinogenesis [174]. Interestingly, cytotoxic NK cell tissue
infiltration positively correlatedwith advanced stages of PTC.
In contrast, the immunoregulatory NK cell population was
negatively associated with tumor stage in patients with PTC.
The tumormicroenvironment can be the sitewhere immature
immunoregulatory cellsmay transform intomature cytotoxic
NK cells, but this developmental program is not entirely fixed,
andmature NK cells can be reeducated by local, environmen-
tal factors. This could probably explain the gradual increase
or decrease in the percentages of NK cell subpopulations
correlating with the tumor stage in their study [174].
6.2. Dendritic Cells. Dendritic cells represent a small subset
of immune cells derived from bone marrow and found
in nearly every tissue in the human body [130]. DCs are
considered to be professional antigen-presenting cells based
on their ability to present antigen in the context of MHC
class II and costimulatory molecules. They are, therefore,
extremely efficient stimulators of immunity and are thought
to be key players in initiating the body’s immune response
[131]. The potential for DCs to amplify immune function in
an antigen-specific manner makes them ideal candidates for
cancer immunotherapy, which attempts to eradicate tumors
by manipulating the body’s own innate immune mechanisms
[131, 132].
Tsuge et al. described the infiltration of DC in DTC.
Thyroid tissues were obtained at thyroidectomy from 85
patients with primary thyroid cancer, most with PTC. PTC
had a higher frequency of CD1a+ immature DCs than
other thyroid tumors. DCs positive for chemokine receptor-
6 (CCR-6) were densely accumulated in PTC [177]. A series
of 527 consecutive cases of thyroid carcinoma treated by total
thyroidectomy was investigated by Ugolini et al.They applied
histopathological and immunohistochemical methods to
investigate inflammatory infiltrate in these tumors. Immature
DCs were detected in PTCs and markedly reduced in poorly
differentiated and undifferentiated thyroid carcinomas, sug-
gesting the protective role of DC and infiltrating lymphocytes
against thyroid tumors [178]. In fact, Hilly investigated
specimens from 69 consecutive patients with PTC, counting
S100+ DC. DC density in PTC correlated with the thyroiditis
grade and DC density in surrounding areas of thyroiditis
[179]. This association suggests that intratumoral infiltration
of DC may be linked to a more complex immunological
phenomenon caused by carcinogenesis.
Pusztaszeri et al. quantitatively assessed the presence
of DCs that were positive for CD1a in cytologic samples
of histologically confirmed PTC and in a control group of
benign thyroid nodules. CD1a-positive DCs were identified
in 97% PTCs in thyroid fine-needle aspiration specimens.
DCs were largely present in two distinct patterns: either
as isolated DCs in the background or as associated with
tumor cells. Both thyrocyte-associated DCs and background
DCs were more numerous in PTC fine-needle aspirations
than in benign thyroid nodule fine-needle aspirations, but
only the thyrocyte-associated group of DCs was statistically
significant, suggesting that malignant cells are able to recruit
DCs during carcinogenesis [180]. Likewise, Proietti et al.
selected 91 consecutive cases of follicular variant of PTC, in
which we evaluated the presence of mature and immature
DCs. In intratumoral and peritumoral areas, the expression
of immature marker of DC was significantly higher in
follicular variant of PTC than in adenomas. Expression of
DC immature marker was comparable in the extratumoral
compartment [181].
Scarpino et al. observed that most DCs are located
in correspondence with the advancing edge of the tumor.
Established primary cultures of neoplastic thyroid cells and
normal cells (from the tumor-free contralateral lobe of the
same patients) obtained from eight thyroids were removed
surgically. Supernatants of both normal thyroid cells and
tumors cells are able to produce chemokines that recruit DC
[182]. This result is an apparent contradiction, since DCs are
rare in normal thyroid tissue, and raises the possibility that
culture conditions may cause stimulatory signals for normal
thyroid cells. In fact, authors previously demonstrated that
normal thyroid cells of primary cultures, but not normal
thyroid cells of tissue sections, express high levels of Met
protein and urokinase-type plasminogen activator receptor,
and both factors stimulate DC recruitment. In addition, Met
protein is expressed in Hu¨rthle cells of Hashimoto thyroiditis
andhyperfunctioning thyrocytes ofGraves’ disease [182–185],
indicating that upregulation of Met receptor is an early event
in thyroid cell alteration. This result may explain the rare
infiltration of DC in benign thyroid lesions [180].
6.3. Mast Cells. Mast cells play an important role in inflam-
matory processes, particularly in the initiation of the immune
response [186]. They are residents of normal connective
tissue and have been widely discussed for their role as
tumor promoters in tumor pathogenesis [187, 188]. To assess
the role of mast cells in human thyroid cancer, Melillo
et al. compared the density of tryptase-positive mast cells
in 96 PTCs versus normal thyroid tissue from 14 healthy
individuals. Mast cell density was higher in 95% of PTCs
than in control tissue. Mast cell infiltrate correlated with
extrathyroidal extension of PTCs. Authors show that thy-
roid cancer cell-line-derived soluble factors induce mast
cell activation and chemoattraction in vitro, suggesting that
mast cells are recruited to tumor microenvironment during
malignant transformation. In addition, Melillo et al. found
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that mast cells induced thyroid cancer cell invasive ability,
survival, and DNA synthesis in vitro, suggesting that mast
cells have a pivotal role in thyroid tumor progression and
dissemination [189]. Proietti et al. evaluated the presence
and distribution of mast cells in follicular variant of PTC
and follicular adenoma. Interestingly, they were significantly
highly expressed in the peritumoral compartment of follicu-
lar variant of PTC. Considering only the follicular variant of
PTC group, there was also a significant correlation between
the abundance of mast cells and the infiltrative pattern
of the tumor [181]. These data corroborate the results of
Acikalin et al., who suggested a protumoral role for mast
cells based on the tight association between these cells
and the promotion of microangiogenesis in tumor tissues
[190].
6.4. Macrophages. Cancer cell recruits monocytes from cir-
culation. Herein, monocytes are induced to differentiate into
macrophages. Phenotypically, macrophage can be recognized
by the expression of CD68. Functionally, there are two
different subsets of macrophages: M1 and M2. M1 main
function is phagocytosis in response to bacterial stimuli
and/or Th1 cytokines, while the main function of M2 is
immunosuppression and trophic activity in response to Th2
cytokines [191, 192].
Herrmann et al. observed that 75 thyroid carcinomas of
follicular cell origin presented rising levels of CD68 positive
cell infiltration associated with dedifferentiation. Positive
correlations could be demonstrated between the density of
CD68-, CD3-, and CD45RO-positive cells and between the
density of CD68-, and CD3-, and CD45RO-positive cells
and vascularisation. These correlations were expected, as the
interaction of CD68-positive cells and T-lymphocytes results
in the production of angiogenic factors, ultimately leading to
better vascularisation of the tumor [193].
Ryder et al. characterized the density of tumor-associated
macrophages (TAM) in well-differentiated, poorly differenti-
ated, and anaplastic thyroid carcinoma and correlated TAM
density with clinicopathological parameters. In total, 27% of
well-differentiated thyroid carcinoma, 54% of poorly differ-
entiated thyroid carcinoma, and 95% of anaplastic thyroid
carcinoma had an increased density of CD68(+) TAMs.
Increased TAMs in poorly differentiated thyroid carcinoma
were associated with capsular invasion and extrathyroidal
extension, and decreased cancer-related survival was com-
pared with poorly differentiated thyroid carcinoma with a
low density of TAMs [194]. The same group used BRAF-
induced PTC mouse models to examine the role of TAMs in
PTC progression. Conditional activation of BRAF in murine
thyroids was associated with a significant increase in the
major TAM chemoattractants. They conditionally depleted
CCR2-dependent TAMs during BRAF induction, resulting
in smaller tumors and decreased proliferation. Phenotypic
analysis demonstrated an increased expression of M2-related
genes such as Ccr2, arginase1, Ccl22, and IL-10, whereas
M1-specific markers (IL-12 and ROS) were not increased.
Selectively depleting TAMs, during advanced stages of PTC,
induce tumor regression. Authors suggested that, as TAMs
promote PTC progression, these cells may be a rational ther-
apeutic target for patients with refractory advanced PTCs,
particularly poorly differentiated and anaplastic thyroid car-
cinoma [195]. However, probable macrophages do not exert
the same role in poorly differentiated thyroid carcinoma and
well-differentiated thyroid carcinoma.
We studied 398 patients with DTC and 132 with non-
malignant tissues [196]. We found TAM more frequently in
more aggressive cases, with metastasis at diagnosis; how-
ever, paradoxically, macrophage infiltration correlated with
improved disease-free survival [196]. How can we explain
the apparent contradictory results? It is possible that these
different results lie on different microenvironments. In fact,
Fiumara et al. studied 121 well-differentiated PTCs and found
tumors with TAM and in situ evidence of active neoplas-
tic cell phagocytosis [197]. Neoplastic cell phagocytosis by
macrophages was positively correlated with infiltration of
lymphocytes andDCs, while it was negatively correlated with
vascular invasion [197]. They also found a trend of a reduced
risk of distant metastases at follow-up in cases with TAM
that, in addition, was associated with lymphocytic infiltration
[196, 197]. Again, an infiltration of mixture of immune cells
can be noted in thyroid tumor microenvironment, and the
prognosis of patients with DTC may be influenced by the
complex interaction between these immune cells.
6.5. Tumor Infiltrating Lymphocytes. Unfortunately, macro-
phages and other innate immune cells cannot always effi-
ciently eliminate tumor cells. However, macrophages and
DCs play an important role in the initiation and subsequent
direction of adaptive immune responses mediated by lym-
phocytes [198]. In addition to providing a more versatile
defense response, lymphocytes provide increased protection
against subsequent reinfection with the same pathogen [198].
Then, unlike innate immune responses, adaptive responses
are highly specific to the particular antigen that induced
them. They can also provide long-lasting protection through
a mechanism called memory. A person who recovers from
measles, for example, is protected for life against measles
by the adaptive immune system, although not against other
common viruses, such as those that cause mumps or chick-
enpox [199]. How does the adaptive immune system work in
a context of tumor development and progression?
Matsubayashi et al. were concerned about the influence
of tumor infiltrating lymphocytes (TIL) and the prognosis
of patients with PTC. They studied 95 patients with PTC
who received primary surgical treatment in 1983 and were
followed until 1992. They observed that 36 patients (group
A) with PTC also presented with an associated TIL, whereas
59 patients (group B) had no TIL. Recurrence of the tumor
was found in only one patient in group A (2.8%), but in
11 patients in group B (18.6%). The percentage of patients
free from recurrence over a 10-year follow-up period in
group A was significantly higher than that in group B,
suggesting that TIL might be used for predicting a favorable
prognosis [1]. Villagelin et al. investigated 157 consecutive
patients with PTC. They were classified by the degree of
TIL: diffuse, peritumoral (only in or around the tumor),
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or absent TIL. After a mean follow-up period of 8 years,
they observed a significantly high recurrence in the absent
lymphocyte infiltration group when compared with patients
from the diffuse and peritumoral lymphocyte infiltration
groups, suggesting that the presence of TIL may favor the
prognosis of patients with PTC [200]. However, lymphocytes
are pool of cells in which multiple phenotypes can be found.
Then, it is very important to assess different subsets of TIL to
study prognostic prediction.
Modi et al. examined 21 PTCs from patients aged 21
years or younger for the presence of CD4+ (helper), CD8+
(killer), CD19+ (B cells), and CD56+ (natural killer) cells.
During follow-up, none of the PTCs containing either CD8+
lymphocytes or the combination of CD4+, CD8+, andCD19+
lymphocytes recurred. Unfortunately, the cohort was too
small and the follow-up inadequate to provide accurate
information on the clinical impact of these immunological
findings [2]. French et al. obtained opposite results. They
investigated whether TIL, in the absence of concurrent CLT,
contributes to disease severity. One hundred PTC patients
were analyzed for concurrent CLT and TIL, and 10 PTC
patients with TIL were assessed for lymphocyte subsets
by immunohistofluorescence. Patients with TIL exhibited
higher disease stage and increased incidence of invasion and
lymph node metastasis compared with those without TIL
or with concurrent CLT. CD4(+) T-cell frequency correlated
with tumor size, FoxP3(+) regulatory T-cell (Treg) frequency
correlatedwith lymph nodemetastasis, andCD8 to Treg ratio
inversely correlated with tumor size [5]. What does the study
of TIL subsets say to us?
CD4+ T cells play a central role in orchestration of the
immune response. Naive CD4+ T-cells may differentiate into
one of at least four functionally distinct populations of cells:
Th1, Th2, Tregs, or Th17. Th1 polarization is characterized
by the production of interferon (IFN)-𝛾 and supports the
cytotoxic response mediated by CD8+ T. In fact, IFN-𝛾
has direct effects on tumor cell immunogenicity and thus
plays an important role in promoting tumor cell recognition
and elimination [87]. Conversely, Th2 polarization stimu-
lates humoral immunity, and recent advances support the
hypothesis that enhanced states of local humoral and innate
immune activation, in combination with suppressed cellular
immunity and failed cytotoxic T-cell antitumor immunity,
alter cancer risk toward tumor promotion and progression.
In general, Treg are identified as FoxP3+ lymphocytes [88].
According to the origin, Treg can be categorized in natural
Treg (originate in the thymus) or inducible Treg (originate
under specific conditions) [86]. Both are thought to con-
tribute to tumor-specific T-cell tolerance [201]. The recent
discovery of Th17 cells and their important role in host
protection against infectious pathogens and in the patho-
genesis of various inflammatory and autoimmune diseases
have resulted in an explosion of immunological research.
However, their part in human cancer is still under investi-
gation [202]. Recently, Moretti et al. evaluated indoleamine
2,3-dioxygenase 1 (IDO1) expression in thyroid carcinoma.
IDO1 catalyzes tryptophan degradation to kynurenine and
appears to exert an immunosuppressive function as part
of an acquired mechanism of immune escape mediated by
the inhibition of lymphocyte proliferation and survival and
by the induction of Treg. Authors demonstrated that IDO1
expression was elevated in thyroid carcinoma compared to
normal thyroid tissue. In addition, IDO1 expression magni-
tude was correlated with both infiltration of Treg and gain of
aggressiveness (PTCs and medullary thyroid carcinomas ≪
anaplastic thyroid carcinomas) [203].
Aiming at better characterizing TIL in DTC microenvi-
ronment, we studied 398 patients, 253 with PTC, 13 with fol-
licular thyroid cancers, and 132 with benign thyroid lesions.
Our data demonstrated that the presence of concurrent CLT
and infiltration of CD4+, CD8+, CD20+, Th17, and Treg
cells are associated with favorable prognostic features in
patients with DTC. Immune cells were found to infiltrate
malignant tissues more often than benign lesions, suggesting
an immune reaction of the organism against transformed
cells [196]. However, how the immune response may alter the
outcome of patients with DTC is not that simple. Prognosis
seems to be an output of complex interactions between the
immune system and tumor cells. In fact, our data indicate
that immune cell infiltration is closely associated with the
immunohistochemical profile of the DTC specimens exam-
ined, including proteins whose expression might indicate
tumor differentiation and progression, demonstrating tumor
antigenicity (NIS, MUC1, PTEN, ATM, and B7H1) [204–
207]. A special attention must be given to B7H1.
Tumors may escape from immune response through
several mechanisms. One of these mechanisms is the upregu-
lation of B7H1 expression. B7H1 is a cell surface glycoprotein
and aberrant tumor expression of B7H1 is thought to be
associated with inhibition of the immune system [208]. As
expected, B7H1 expression in tumor cells has been associated
with poor prognosis in some epithelial cancers [209]. We
demonstrated that both B7H1 protein and B7H1 mRNA are
upregulated in differentiated thyroid carcinomas, contrasting
with the low levels displayed by benign tissues [210]. We
also observed an association between high B7H1 mRNA
levels and an aggressive phenotype, like higher stages at
presentation and increased age at diagnosis, suggesting that
high levels of B7H1 expression may identify individuals
who need a more aggressive approach [210]. Interestingly,
we observed that lymph node metastatic tissues, compared
with respective matched primary tumor tissue, had lower
levels of B7H1, indicating T-cell exhaustion [210]. In fact,
French et al. recently described high levels of IFN+/CD8+
T-cells in metastatic lymph node tissues excised during the
initial surgery, at patient presentation [211]. They found that
proliferating lymphocytes were evident in tumor-involved
lymph node metastases that were enriched with B7H1-
ligand+ lymphocytes [211]. Authors hypothesized that the
presence of metastases may promote an IFN+ response,
suggesting the generation of an antitumor response, which
may impair tumor evasion. In fact, this could explain the
decrease in B7H1 expression that we observed in ourmatched
metastases, indicating that T-cell exhaustion is a mechanism
of tumor progression.
Gupta et al. hypothesized that TIL with a high prolifera-
tion index would be found in thyroid cancers from children
and young adults and would be associated with improved
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disease-free survival. Using immunohistochemistry, they
examined 39 childhood PTC, 9 FTC, 2 medullary thyroid
carcinomas, 11 benign thyroid lesions, and 2 normal thyroid
glands for the presence of lymphocytes and lymphocyte
proliferation. Disease-free survival did not correlate with the
presence or number of lymphocytes per high-power field.
In contrast, disease-free survival was significantly improved
for thyroid cancers with the greatest number of proliferating
lymphocytes per high-power field [6].
7. Medullary Thyroid Carcinoma and
Immune Response
Medullary thyroid carcinoma (MTC), arising fromparafollic-
ular, calcitonin-producing C-cells, represents an aggressive,
usually slow-growing tumor occurring in both sporadic and
familial forms such as multiple endocrine neoplasia type 2
[212].
Sporadic MTC harbors RET gene somatic mutations in
up to 50% of cases, and RAS family gene mutations occur
in about 10% [213]. Simbolo et al. investigated 20 surgically
resected sporadic MTCs. Thirteen (65%) MTCs harbored a
RET mutation; four cases harbored a RAS mutation: three
in HRAS and one in KRAS [213]. On the other hand,
hereditary MTC is one of the most successful applications
of genetics knowledge in medical practice. The discovery of
mutations in the RET protooncogene resulting in variable
onset and severity of multiple endocrine neoplasia type 2
was the first step in developing direct genetic testing for at-
risk individuals. Patients with germline RET mutations may
undergo risk assessment and appropriate intervention based
on specific mutations [214]. Clinicians are therefore able to
make better therapeutic choices guided by an informative
biomarker, reinforcing the current concept of an increasingly
personalized medicine [214].
No conventional therapy has been established for the
metastatic state, since MTC usually presents low chemosen-
sitivity and radiosensitivity. In contrast, C-cells of the thy-
roid gland are of neuroendocrine origin and may therefore
be highly susceptible to an immune attack, as are other
neuroendocrine cells such as 𝛽-cells of the pancreas in
autoimmune type 1 diabetes mellitus or parathyroid cells
in autoimmune hypoparathyroidism [215–217]. All these
features encouraged immunologists and endocrinologists to
test cancer immunotherapy against MTC.
It has been known for a long time that the immune system
plays a role in MTC [218, 219]. In fact, Mu¨ller et al. [220]
observed an increase of FoxP3+ lymphocytes in peripheral
blood of patients with MTC but not in patients with benign
goiter; this increase also correlates with findings in lymph
nodes and thyroid gland. Authors found that the number of
FoxP3+ cells correlated with the patients’ prognosis. After
clinical staging (International Union against Cancer-UICC-
stages) of MTC patients, triplication of FoxP3+ lymphocytes
could be observed from MTC < UICC II to MTC > UICC
II, suggesting that the immune system could interfere in
outcome of patients with MTC.
Different proteins are known to be the possible target
molecules for immunotherapy in MTC. Calcitonin is the
most important target molecule. Zhang et al. performed an
epitopemappingwithmonoclonal antibodies and the highest
immunogenicity of the central region of calcitonin (amino
acids 13–21) was shown [221]. Haupt et al. [222] investigated
how immunogenic calcitonin is. Antigen-encoding expres-
sion plasmids were delivered intradermally by gene gun. One
group of mice received DNA encoding human precursor
protein preprocalcitonin only. Two groups were coinjected
with mouse cytokine genes. They observed in lymphocyte
proliferative assays substantial proliferation against human
precursor protein preprocalcitonin in mice coinjected with
the granulocyte-macrophage colony-stimulating factor gene,
in contrast to mice vaccinated with human precursor protein
preprocalcitonin expression plasmid only, suggesting that
cellular and humoral immune responses against human
precursor protein preprocalcitonin can be generated by DNA
immunization. Conversely, codelivery of IFN-𝛾 expression
plasmid resulted in a decreased antibody response against
human precursor protein preprocalcitonin, probably due to
enhanced Th1-like immunity. Wuttke et al. [223] studied
amino acid-modified calcitonin. Mice were immunized over
six months with monthly injections of amino acid-modified
CT-pulsed dendritic cells. CT-immunized mice showed evi-
dences of antitumor immune response, with an intratumor
infiltration with CD8+ T lymphocytes. Importantly, they
also found a diminished tumor outgrowth and a decrease
in serum CT levels compared with control mice, suggesting
that amino acid-modified CT is recognized from the immune
system leading to an effective specific antitumor immune
response. This result raises the idea that immunotherapy
strategies against MTC would be key point for MTC treat-
ment.
Anti-MTC cancer vaccines are the most important strat-
egy of immunotherapy against MTC. Therapeutic cancer
vaccines are intended to activate the immune system for
treating an existing tumor or preventing its recurrence.
Since DCs are highly potent antigen-presenting cells and
are able to orchestrate immune response, they represent
an excellent tool for immunization against cancer [224].
Schott et al. reported on a clinical trial of DC vaccination
in metastasized MTC [225]. Seven patients were enrolled
in this study. Mature DCs were generated from peripheral
bloodmonocytes in the presence of granulocyte-macrophage
colony-stimulating factor, IL-4, and TNF𝛼. After, DCs were
loaded with calcitonin and carcinoembryonic antigen (CEA)
peptide and repeatedly delivered by sc injections. In three
of seven patients, clinical responses with a decrease in
serum calcitonin and CEA were initially documented. One
of these patients had a complete regression of detectable
liver metastases and a significant reduction of pulmonary
lesions. This patient presented with a calcitonin- and CEA-
specific immunreactivity [225]. All seven patients developed
a strong delayed-type hypersensitivity skin reaction, which
was confirmed to be mediated by infiltrating CD4+ T-
helper cells and CD8+ cytotoxic T-cells. Measurement of
cytokine release from T lymphocytes demonstrated high
posttreatment interferon-gamma secretion after stimulation
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with calcitonin in five patients. In contrast, antigen-specific
interleukin-4 (IL-4) production was only slightly increased
in four patients, suggesting that an induction of a Th1-
dominated cellular immune response against calcitonin and
CEA in the majority of patients does occur [226].
Stift et al. [227] evaluated the effectiveness of DC vac-
cines in 10 MTC patients. They generated autologous tumor
lysate-pulsed DCs from all patients suffering from advanced
MTC for repeated vaccination. Mature DCs were derived
from peripheral blood monocytes, culture in the presence
of granulocyte-macrophage colony-stimulating factor, inter-
leukin 4, and tumor necrosis factor alpha with or without
addition of IFN-gamma, loadedwith tumor lysate, and finally
further injected into a groin lymph node. Vaccination was
well tolerated and induced a positive immunological response
in all of the tested patients. Three patients had a partial
response, one patient presented a minor response, and two
patients showed stable disease at least 29 months after the
start of immunotherapy. The remaining four patients had
progressive disease [227].
Bachleitner-Hofmann et al. [228] performed a pilot trial
of autologous DCs pulsed with tumor cell lysate derived
from allogeneic MTC cell lines in 10 patients with metastatic
MTC. DCs were injected into a groin lymph node at 3-
week intervals, followed by serial calcitonin tumor marker
measurements; radiological imaging and immunological in
vitro tests were monitored. After a median follow-up of
11 months, three patients had stable disease, while seven
progressed during treatment. In two patients with stable dis-
ease, calcitonin decreased below treatment levels, paralleled
by a T-cell mediated immune response. Notably, treatment
with DCs pulsed with a combination of different tumor cell
lysates was followed by a calcitonin decrease in four patients
who had previously experienced a calcitonin increase during
monotherapy with DCs pulsed with a single lysate.
8. Conclusion
The first study that investigated immunotherapy in patients
with follicular cell-derived thyroid cancer came out in 1975
[229]. Active immunotherapy was applied to three patients
with thyroid cancer. Two patients, who were in the terminal
stage of illness, could not develop generalized cell-mediated
immunity and immunization did not alter the patients’ rapid
downhill course. One patient developed in vitro evidence
of cell-mediated immunity against cancer tissue antigens,
associated with decrease in tumor size. Unfortunately, four
months after immunization, cell-mediated immunity was
impaired in autologous plasma culture, but not in cultures in
allogeneic normal plasma.
More than 40 years later, no significant advance has been
made in immunotherapy for follicular cell-derived thyroid
tumors. In part, this can be explained by the success of
current therapy, which is able to solve the problem of 95%
of patients diagnosed with DTC. However, it is notewor-
thy that immunotherapy is not the unique application of
antitumor immune response. Infiltration of immune cells
may predict outcome, and this is an important practical
advance in the thyroid field, perhaps even more impor-
tant than immunotherapy. The immune system gives us
tools to identify more aggressive tumors and patients who
may benefit from a more invasive approach, sparing the
vast majority of patients with an indolent disease from
unnecessary procedures. The recognition of immune aspects
underlying thyroid cancer development and progressionmay
help physicians to perform a more personalized approach to
their patients. In fact, tumor immunology understanding has
widened our boundaries.
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